Evercore ISI Group Downgrades Zimmer Biomet Holdings to In-Line, Lowers Price Target to $125
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Vijay Kumar downgraded Zimmer Biomet Holdings (NYSE:ZBH) from Outperform to In-Line and reduced the price target from $135 to $125.
January 04, 2024 | 5:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Zimmer Biomet Holdings was downgraded by Evercore ISI Group from Outperform to In-Line, with a price target decrease from $135 to $125.
Downgrades by analysts can lead to a negative perception among investors, potentially causing a short-term decline in the stock price. The reduction in the price target further suggests a tempered expectation for the company's future performance, which may also contribute to downward pressure on the stock.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100